Consilium Wealth Advisory LLC Makes New Investment in Danaher Corporation $DHR

Consilium Wealth Advisory LLC purchased a new position in shares of Danaher Corporation (NYSE:DHR) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 2,618 shares of the conglomerate’s stock, valued at approximately $580,000.

Other large investors have also modified their holdings of the company. Investment Planning Advisors Inc. acquired a new stake in shares of Danaher in the 3rd quarter worth approximately $2,540,000. Adirondack Trust Co. increased its stake in shares of Danaher by 536.1% during the third quarter. Adirondack Trust Co. now owns 13,963 shares of the conglomerate’s stock valued at $3,094,000 after acquiring an additional 11,768 shares during the period. Three Magnolias Financial Advisors LLC acquired a new position in shares of Danaher during the third quarter valued at approximately $939,000. Seelaus Asset Management LLC bought a new stake in Danaher during the third quarter worth approximately $1,007,000. Finally, Navigate Wealth Management LLC bought a new stake in Danaher during the third quarter worth approximately $2,549,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a favorable combination of earnings-estimate revisions and its Earnings ESP, suggesting the company could exceed consensus expectations in its upcoming report. This is supporting optimism ahead of results. Danaher Earnings Expected to Grow
• Positive Sentiment: NVIDIA AI partnership: Danaher announced a collaboration with NVIDIA to combine its scientific instruments, automation systems, laboratory workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative could improve laboratory productivity and strengthen Danaher’s long-term growth prospects. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous-lab opportunity: Danaher plans to launch its first AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027. Although the initial market reaction was limited, the move gives investors another potential growth avenue in life-science automation and AI-driven drug discovery. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support and board changes: Morgan Stanley maintained its $240 price target, while Danaher expanded its board to 13 members with the appointments of Daniel Comas and Robert Hershberg. These developments provide stability but are not expected to materially change near-term earnings. Morgan Stanley Maintains Danaher Price Target
• Neutral Sentiment: Upcoming earnings focus: Investors are monitoring the company’s projected earnings announcement, with expectations for earnings growth likely to keep attention on execution and forward guidance. Danaher Projected Earnings Announcement

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on DHR shares. Wells Fargo & Company cut their target price on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a research report on Saturday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $240.00 price objective on shares of Danaher in a research note on Wednesday, July 22nd. Weiss Ratings upgraded Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Finally, Guggenheim raised their target price on Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Price Performance

Shares of NYSE DHR traded up $1.44 during mid-day trading on Wednesday, reaching $224.28. The company had a trading volume of 1,890,805 shares, compared to its average volume of 4,448,106. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The stock has a market cap of $157.66 billion, a PE ratio of 39.79, a P/E/G ratio of 2.78 and a beta of 0.76. The company has a 50-day moving average price of $212.41 and a two-hundred day moving average price of $195.13. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80.

Danaher (NYSE:DHR) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the prior year, the business posted $0.77 earnings per share. Danaher’s revenue was up 5.5% compared to the same quarter last year. On average, equities analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s payout ratio is presently 28.42%.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.